Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
Junghoon Shin(Seoul National University Bundang Hospital), Jong Seok Lee(Brigham and Women's Hospital)
Cited by 110
Related Papers
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
|The Lancet Oncology|2022|738
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
|Lung Cancer|2024|66
Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer
|American Journal of Clinical Oncology|2005|55
Phase II Study of Low-Dose Docetaxel/Fluorouracil/Cisplatin in Metastatic Gastric Carcinoma
|American Journal of Clinical Oncology|2005|44